JP7785023B2 - アデノ関連ウイルス抗体及びそのフラグメント - Google Patents

アデノ関連ウイルス抗体及びそのフラグメント

Info

Publication number
JP7785023B2
JP7785023B2 JP2022575373A JP2022575373A JP7785023B2 JP 7785023 B2 JP7785023 B2 JP 7785023B2 JP 2022575373 A JP2022575373 A JP 2022575373A JP 2022575373 A JP2022575373 A JP 2022575373A JP 7785023 B2 JP7785023 B2 JP 7785023B2
Authority
JP
Japan
Prior art keywords
seq
acid sequence
amino acid
set forth
sequence set
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022575373A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023529417A (ja
JP2023529417A5 (https=
Inventor
ソーラブ カーン，
ダニエル グリフィン，
ルイーズ ロディーノ－クラパック，
Original Assignee
サレプタ セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サレプタ セラピューティクス， インコーポレイテッド filed Critical サレプタ セラピューティクス， インコーポレイテッド
Publication of JP2023529417A publication Critical patent/JP2023529417A/ja
Publication of JP2023529417A5 publication Critical patent/JP2023529417A5/ja
Application granted granted Critical
Publication of JP7785023B2 publication Critical patent/JP7785023B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Environmental Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2022575373A 2020-06-15 2021-06-15 アデノ関連ウイルス抗体及びそのフラグメント Active JP7785023B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063038957P 2020-06-15 2020-06-15
US63/038,957 2020-06-15
PCT/US2021/037314 WO2021257497A1 (en) 2020-06-15 2021-06-15 Adeno-associated virus antibodies and fragments thereof

Publications (3)

Publication Number Publication Date
JP2023529417A JP2023529417A (ja) 2023-07-10
JP2023529417A5 JP2023529417A5 (https=) 2024-06-19
JP7785023B2 true JP7785023B2 (ja) 2025-12-12

Family

ID=77398628

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022575373A Active JP7785023B2 (ja) 2020-06-15 2021-06-15 アデノ関連ウイルス抗体及びそのフラグメント

Country Status (4)

Country Link
US (2) US12391745B2 (https=)
EP (1) EP4165076A1 (https=)
JP (1) JP7785023B2 (https=)
WO (1) WO2021257497A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3596112A2 (en) 2017-03-17 2020-01-22 Newcastle University Adeno-associated virus vector delivery of a fragment of micro-dystrophin to treat muscular dystrophy
MY208145A (en) 2018-06-18 2025-04-18 Res Inst Nationwide Childrens Hospital Adeno-associated virus vector delivery of muscle specific micro-dystrophin to treat muscular dystrophy
US12391745B2 (en) 2020-06-15 2025-08-19 Sarepta Therapeutics, Inc. Adeno-associated virus antibodies and fragments thereof
WO2023196892A1 (en) 2022-04-06 2023-10-12 The Trustees Of The University Of Pennsylvania Passive immunization with anti- aav neutralizing antibodies to prevent off-target transduction of intrathecally delivered aav vectors
WO2024140627A1 (zh) * 2022-12-26 2024-07-04 南京金斯瑞生物科技有限公司 抗多种血清型aav衣壳蛋白的单克隆抗体及其制备方法和用途
EP4705768A1 (en) * 2023-05-05 2026-03-11 Regeneron Pharmaceuticals, Inc. Labeling and anti-drug antibody assays for aav vectors
CN116751284B (zh) * 2023-06-13 2024-06-04 康元医疗科技(大连)有限公司 一种纳米抗体、包含该纳米抗体的多肽及其应用
WO2025083119A1 (en) * 2023-10-18 2025-04-24 Svar Life Science Ab Assessment of aav-mediated complement activation potential
WO2025100417A1 (ja) * 2023-11-06 2025-05-15 株式会社ダイセル Ａａｖのフルカプシドに対するアフィニティポリペプチド
CN117229393B (zh) * 2023-11-10 2024-01-30 北京百普赛斯生物科技股份有限公司 特异性结合腺相关病毒5的抗体及其应用
WO2026069251A1 (en) * 2024-09-30 2026-04-02 Sarepta Therapeutics, Inc. Adeno-associated virus capsid antibodies and fragments thereof
CN119080918A (zh) * 2024-10-11 2024-12-06 杭州艾策生物技术有限公司 一种包含aav-x抗原结合结构域的结合蛋白
CN120314575B (zh) * 2025-06-16 2025-08-29 重庆原伦生物科技有限公司 一种利用双抗体夹心定量检测PreScission蛋白酶含量的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013123503A1 (en) 2012-02-17 2013-08-22 The Children's Hospital Of Philadelphia Aav vector compositions and methods for gene transfer to cells, organs and tissues
WO2016176212A1 (en) 2015-04-27 2016-11-03 The Trustees Of The University Of Pennsylvania Engineered human anti-aav antibodies and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5814318A (en) * 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US9434928B2 (en) 2011-11-23 2016-09-06 Nationwide Children's Hospital, Inc. Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides
WO2017078839A1 (en) * 2015-11-02 2017-05-11 Bioatla, Llc Conditionally active polypeptides
US12391745B2 (en) 2020-06-15 2025-08-19 Sarepta Therapeutics, Inc. Adeno-associated virus antibodies and fragments thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013123503A1 (en) 2012-02-17 2013-08-22 The Children's Hospital Of Philadelphia Aav vector compositions and methods for gene transfer to cells, organs and tissues
WO2016176212A1 (en) 2015-04-27 2016-11-03 The Trustees Of The University Of Pennsylvania Engineered human anti-aav antibodies and uses thereof

Also Published As

Publication number Publication date
WO2021257497A1 (en) 2021-12-23
US11472866B2 (en) 2022-10-18
US12391745B2 (en) 2025-08-19
US20210388064A1 (en) 2021-12-16
US20220033478A1 (en) 2022-02-03
JP2023529417A (ja) 2023-07-10
EP4165076A1 (en) 2023-04-19

Similar Documents

Publication Publication Date Title
JP7785023B2 (ja) アデノ関連ウイルス抗体及びそのフラグメント
Sunwoo et al. Quantitative and sensitive detection of the SARS-CoV spike protein using bispecific monoclonal antibody-based enzyme-linked immunoassay
CN113214393A (zh) Il-6抗体或其抗原结合片段及包含其的检测试剂盒
JP7359390B2 (ja) チクングニアウイルスに対する抗体またはその抗原結合断片、およびその用途
CN109336973B (zh) 抗转铁蛋白抗体及其用途
KR20210114923A (ko) 항 열대열 말라리아 원충 hrp-ii 항체
CN118146380B (zh) 基于ai从头设计筛选合成的her2蛋白特异性结合抗体及其应用
KR20190054779A (ko) 치쿤구니아 바이러스 감염 진단용 단일클론항체, 이를 생산하는 하이브리도마 및 이를 이용한 치쿤구니아 바이러스 감염 진단 방법
WO2026069251A1 (en) Adeno-associated virus capsid antibodies and fragments thereof
CN112646029B (zh) 成熟脑源性神经营养因子的抗体及其应用和诊断试剂盒
EP4444424A1 (en) Camelid antibodies for use in therapy and diagnosis
CN118234864A (zh) 抗EphA4抗体
CN112574305A (zh) 针对前体脑源性神经营养因子的抗体及其应用
WO2026069244A1 (en) Sarcoglycan antibodies and fragments thereof
CN119775400B (zh) 一种结合h3n2 ha蛋白的全人源单克隆抗体mz001和应用
WO2026075999A2 (en) Dystrophin and micro-dystrophin antibodies and fragments thereof
CN120192419B (zh) 抗鼠免疫球蛋白G2a亚型（IgG2a）的兔单克隆抗体mAb6及其应用
CN120795137B (zh) 抗gii.2型诺如病毒抗体或其抗原结合片段及其制备方法与应用
CN119431591B (zh) 抗人psp蛋白的单克隆抗体及其应用
CN120829501B (zh) 抗gii.6型诺如病毒抗体或其抗原结合片段及其制备方法与应用
CN117304313B (zh) 一种特异性结合鼠疫耶尔森菌v抗原的全人源单克隆抗体
US20190375834A1 (en) Disulfide-type hmgb1-specific antibody, method for measuring disulfide-type hmgb1 and kit for said measurement, and measurement method capable of quantitating all of hmgb1 molecules including reduced hmgb1, disulfide-type hmgb1 and thrombin-cleavable hmgb1 and kit for said measurement
JPWO2017033846A1 (ja) 免疫試験方法および免疫試験キット
JP6531262B2 (ja) 抗蛍光色素モノクローナル抗体
CN118255883A (zh) 针对人视锥蛋白样蛋白1的单克隆抗体、抗体对和试剂盒及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240610

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240610

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250922

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251104

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251128

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251202

R150 Certificate of patent or registration of utility model

Ref document number: 7785023

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150